199 related articles for article (PubMed ID: 28691927)
1. Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.
Wang YT; Chen J; Chang CW; Jen J; Huang TY; Chen CM; Shen R; Liang SY; Cheng IC; Yang SC; Lai WW; Cheng KH; Hsieh TS; Lai MZ; Cheng HC; Wang YC; Chen RH
J Clin Invest; 2017 Aug; 127(8):2982-2997. PubMed ID: 28691927
[TBL] [Abstract][Full Text] [Related]
2. KLHL39 suppresses colon cancer metastasis by blocking KLHL20-mediated PML and DAPK ubiquitination.
Chen HY; Hu JY; Chen TH; Lin YC; Liu X; Lin MY; Lang YD; Yen Y; Chen RH
Oncogene; 2015 Oct; 34(40):5141-51. PubMed ID: 25619834
[TBL] [Abstract][Full Text] [Related]
3. PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
Kuo HY; Huang YS; Tseng CH; Chen YC; Chang YW; Shih HM; Wu CW
Cell Cycle; 2014; 13(19):3132-42. PubMed ID: 25486572
[TBL] [Abstract][Full Text] [Related]
4. PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes.
Ponente M; Campanini L; Cuttano R; Piunti A; Delledonne GA; Coltella N; Valsecchi R; Villa A; Cavallaro U; Pattini L; Doglioni C; Bernardi R
JCI Insight; 2017 Feb; 2(4):e87380. PubMed ID: 28239645
[TBL] [Abstract][Full Text] [Related]
5. SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.
Lin YC; Lu LT; Chen HY; Duan X; Lin X; Feng XH; Tang MJ; Chen RH
Cancer Res; 2014 Dec; 74(23):6935-46. PubMed ID: 25293974
[TBL] [Abstract][Full Text] [Related]
6. The PML isoform IV is a negative regulator of nuclear EGFR's transcriptional activity in lung cancer.
Kuo HY; Chen YC; Chang HY; Jeng JC; Lin EH; Pan CM; Chang YW; Wang ML; Chou YT; Shih HM; Wu CW
Carcinogenesis; 2013 Aug; 34(8):1708-16. PubMed ID: 23563092
[TBL] [Abstract][Full Text] [Related]
7. The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein.
Guan D; Factor D; Liu Y; Wang Z; Kao HY
Oncogene; 2013 Aug; 32(33):3819-28. PubMed ID: 22945642
[TBL] [Abstract][Full Text] [Related]
8. The role of PML ubiquitination in human malignancies.
Chen RH; Lee YR; Yuan WC
J Biomed Sci; 2012 Aug; 19(1):81. PubMed ID: 22935031
[TBL] [Abstract][Full Text] [Related]
9. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
10. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
11. PML degradation fosters an immunosuppressive and pro-metastatic tumor microenvironment.
Wang YT; Chen RH
Mol Cell Oncol; 2017; 4(6):e1364212. PubMed ID: 29209651
[TBL] [Abstract][Full Text] [Related]
12. PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.
Song C; Wang L; Wu X; Wang K; Xie D; Xiao Q; Li S; Jiang K; Liao L; Yates JR; Lee JD; Yang Q
Cancer Res; 2018 May; 78(10):2475-2489. PubMed ID: 29735542
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
15. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
[TBL] [Abstract][Full Text] [Related]
16. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Choi S; Baldini C; Konstantinidou G; Pandolfi PP
Mol Cell Biochem; 2008 Sep; 316(1-2):149-54. PubMed ID: 18566754
[TBL] [Abstract][Full Text] [Related]
17. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
18. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
[TBL] [Abstract][Full Text] [Related]
19. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
20. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
